Actym Therapeutics, a biotech focused on the discovery and development of novel cancer therapies, and Wacker Biotech, have signed a contract for the manufacturing of Actym’s lead clinical candidate, ACTM-838, for the treatment of solid tumors.
Wacker Biotech will initiate GMP (Good Manufacturing Practice) production of Phase 1 clinical material of Actym’s therapeutic candidate at its site in Amsterdam using its LIBATEC technology. Both companies announced today that they are already working closely together on technology transfer and initiation of scale-up production of ACTM-838.
